These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38174749)

  • 1. Biotechnological therapeutic in Juvenile Idiopathic Arthritis: Pathophysiological implications and targeted therapies.
    Pinto AM; Ascenção I; Rodrigues M; Brito I
    ARP Rheumatol; 2023; 2(4):299-306. PubMed ID: 38174749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid factor value for determining the first biologic agent to use for non-systemic juvenile idiopathic arthritis.
    Yamasaki Y; Nakamura A; Kubota T; Mitsunobu T; Moriyama M; Takei S; Okamoto Y
    Mod Rheumatol; 2023 Nov; 33(6):1171-1175. PubMed ID: 36197747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.
    Brunner HI; Schanberg LE; Kimura Y; Dennos A; Co DO; Colbert RA; Fuhlbrigge RC; Goldmuntz E; Kingsbury DJ; Patty-Resk C; Mintz S; Onel K; Rider LG; Schneider R; Watts A; von Scheven E; Lovell DJ; Beukelman T;
    Arthritis Rheumatol; 2020 Nov; 72(11):1945-1951. PubMed ID: 32524767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
    Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
    Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
    Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
    Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
    Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
    Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
    Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Baris HE; Anderson E; Sozeri B; Dedeoglu F
    Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for the withdrawal of classic and biological DMARD in clinically inactive patients with juvenile idiopathic arthritis.
    Azevedo SA; Ramos Rodrigues J; Guimarães F; Almeida D; Pinto AS; Parente H; Peixoto D
    Acta Reumatol Port; 2020; 45(3):229-232. PubMed ID: 33139687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
    Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
    Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.